News | January 30, 2026
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Heart failure affects an estimated 64.3 million people worldwide
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Subscribe To Our Newsletter & Stay Updated
